Current concepts in the management of hepatopulmonary syndrome

Vascular Health and Risk Management

Volumn 4, Issue 5, 2008, Pages 1035-1041

  Ho, Vincent ^a  

^a JAMES COOK UNIVERSITY   (Australia)

Author keywords

Hepatopulmonary syndrome; Liver cirrhosis; Lung diseases

Indexed keywords

ALBUMIN TC 99M; ALMITRINE DIMESILATE; ANTIBIOTIC AGENT; GARLIC EXTRACT; ILOPROST; OXYGEN; PENTOXIFYLLINE;

ARTERIAL GAS; ARTERIAL OXYGEN SATURATION; CLINICAL FEATURE; COIL EMBOLIZATION; CONTRAST ENHANCEMENT; DEOXYGENATION; DIAGNOSTIC IMAGING; DYSPNEA; ECHOCARDIOGRAPHY; HEPATOPULMONARY SYNDROME; HUMAN; LIVER TRANSPLANTATION; LUNG ANGIOGRAPHY; LUNG SCINTISCANNING; NONHUMAN; OXYGEN THERAPY; PATHOGENESIS; PORTAL HYPERTENSION; PROGNOSIS; PULMONARY ARTERIOVENOUS FISTULA; REVIEW; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; UNSPECIFIED SIDE EFFECT; VASOCONSTRICTION; VASODILATATION;

ANOXIA; CARDIOVASCULAR AGENTS; DISEASE PROGRESSION; HEPATOPULMONARY SYNDROME; HUMANS; LIVER TRANSPLANTATION; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; PULMONARY ARTERY; RADIOGRAPHY, INTERVENTIONAL; TREATMENT OUTCOME; VASODILATION;

EID: 56849125737     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Abrams GA, Jaffe CC, Hoffer PB, et al. 1995. Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome. Gastroenterology, 109:1283-8.
2. Abrams GA, Nanda NC, Dubovsky EV, et al. 1998. The use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: a new approach. Gastroenterology, 114:305-10.
3. Abrams GA, Fallon MB. 1998. Treatment of hepatopulmonary syndrome with Allium sativum L. (garlic): a pilot trial. J Clin Gastroenterol, 27:232-5.
4. Alizadeh AHM, Fatemi SR, Mirzaee V, et al. 2006. Clinical features of hepatopulmonary syndrome in cirrhotic patients. World J Gastroenterol, 12:1954-6.
5. Allgaier HP, Haag K, Ochs A, et al. 1995. Hepatopulmonary syndrome: successful treatment by transjugular intrahepatic portosystemic stent-shunt (TIPS). J Hepatol, 23:102-5.
6. Andrivet P, Cadranel J, Housset B, et al. 1993. Mechanisms of impaired arterial oxygenation in patients with liver cirrhosis and severe respiratory insufficiency. Effects of indomethacin. Chest, 103:500-7.
7. Arguedas M, Abrams GA, Krowka MJ, et al. 2003. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology, 37:192-7.
8. Berthelot P, Walker JG, Sherlock S, et al. 1966. Arterial changes in the lungs in cirrhosis of the liver - lung spider nevi. N Engl J Med, 274:291-8.
9. Bruix J, Bosch J, Kravetz D, et al. 1985. Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology, 88:430-5.
10. Brussino L, Bucca C, Morello M, et al. 2003. Effect on dyspnoea and hypoxemia of inhaled NG-nitro-L-arginine methyl ester in hepatopulmonary syndrome. Lancet, 362:43-4.
11. Cadranel J, Milleron B, Cadranel JF, et al. 1992. Severe hypoxemia associated intrapulmonary shunt in a patient with chronic liver disease: improvement after medical treatment. Am Rev Respir Dis, 146:526-7.
12. Castro M, Krowka MJ. 1996. Hepatopulmonary syndrome: a pulmonary vascular complication of liver disease. Clin Chest Med, 17:35-48.
13. Cremona G, Higenbottam TW, Mayoral V, et al. 1995. Elevated exhaled nitric oxide in patients with hepatopulmonary syndrome. Eur Respir J, 8:1883-5.
14. Davis HH 2nd, Schwartz DJ, Lefrak SS, et al. 1978. Alveolar-capillary oxygen disequilibrium in hepatic cirrhosis. Chest, 73:507-11.
15. De BK, Sen S, Biswas PK, et al. 2000. Hepatopulmonary syndrome in inferior vena cava obstruction responding to cavoplasty. Gastroenterology, 118:192-6.
16. De BK, Sen S, Biswas PK, et al. 2002. Occurrence of hepatopulmonary syndrome in Budd-Chiari syndrome and the role of venous decompression. Gastroenterology, 122:897-903.
17. Edell ES, Cortese DA, Krowka MJ, et al. 1989. Severe hypoxemia and liver disease. Am Rev Respir Dis, 140:1631-5.
18. Fallon MB, Abrams GA, Luo B, et al. 1997. The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome. Gastroenterology, 113:606-14.
19. Fallon MB, Abrams GA. 2000. Pulmonary dysfunction in chronic liver disease. Hepatology, 32:859-65.
20. Fluckiger M. 1884. Vorkommen von trommelschlägelförmigen fingerendphalengen ohne chronische veränderungen an der lungen oder am herzen. Wien Med Wschr, 34:1457.
21. Genovesi MG, Tierney DF, Taplin GV, et al. 1976. An intravenous radionuclide method to evaluate hypoxemia caused by abnormal alveolar vessels. Limitation of conventional techniques. Am Rev Respir Dis, 114:59-65.
22. Gines P, Jimenez W, Arroyo V, et al. 1988. Atrial natriuretic factor in cirrhosis with ascites: Plasma levels, cardiac release and splanchnic extraction. Hepatology, 8:636-42.
23. Henriksen JH, Staun-Olsen P, Fahrenkrug P, et al. 1980. Vasoactive intestinal polypeptide (VIP) in cirrhosis: arteriovenous extraction in different vascular beds. Scand J Gastroenterol, 15:787-92.
24. Hopkins WE, Waggoner AD, Barzilai B. 1992. Frequency and significance of intrapulmonary right-to-left shunting in end-stage hepatic disease. Am J Cardiol, 70:516-19.
25. Hortnagl H, Singer EA, Lenz K, et al. 1984. Substance-P is markedly increased in plasma of patients with hepatic coma. Lancet, 1:480-3.
26. Kamath PS. 2002. Portopulmonary hypertension and hepatopulmonary syndrome. J Gastroenterol Hepatol, 17:S253-5.
27. Karabulut A, Iltumur K, Yalcin K, et al. 2006. Hepatopulmonary syndrome and right ventricular diastolic functions: an echocardiographic examination. Echocardiography, 23:271-8.
28. Kennedy TC, Knudson RJ. 1997. Exercise-aggravated hypoxemia and orthodexia in cirrhosis. Chest, 72:305-9.
29. Krowka MJ, Cortese DA. 1987. Severe hypoxemia associated with liver disease: Mayo Clinic experience and the experimental use of almitrine bimesylate. Mayo Clin Proc, 62:164-73.
30. Krowka MJ, Cortese DA. 1990. Hepatopulmonary syndrome: an evolving perspective in the era of liver transplantation. Hepatology, 11:138-42.
31. Krowka MJ, Dickson ER, Cortese DA. 1993. Hepatopulmonary syndrome. Clinical observations and lack of therapeutic response to somatostatin analogue. Chest, 104:515-21.
32. Krowka MJ. 2000. Hepatopulmonary syndromes. Gut, 40:1-4.
33. Krug S, Seyfarth HJ, Hagendorff A, et al. 2007. Inhaled iloprost for hepatopulmonary syndrome: improvement of hypoxemia. Eur J Gastroenterol Hepatol, 19:1140-3.
34. Lange PA, Stoller JK. 1996. Hepatopulmonary syndrome: effects of liver transplantation. Clin Chest Med, 17:115-23.
35. Lima BL, Franca AV, Pazin-Filho, et al. 2004. Frequency, clinical characteristics, and respiratory parameters of hepatopulmonary syndrome. Mayo Clin Proc, 79:42-8.
36. Martinez-Palli G, Drake BB, Garcia-Pagan JC, et al. 2005. Effect of transjugular intrahepatic portosystemic shunt on pulmonary gas exchange in patients with portal hypertension and hepatopulmonary syndrome. World J Gastroenterol, 11:6858-62.
37. Milhe F, Reynaud-Gaubert M, Magnan A, et al. 2006. Oxygenation improvement with almitrine bismesylate in the hepatopulmonary syndrome. Respiratory Medicine Extra, 2:81-4.
38. Naejie R, Hallemans R, Mols P, et al. 1981. Hypoxic pulmonary vasoconstriction in liver cirrhosis. Chest, 80:570-4.
39. Naejie R, Dinh-Xuan AT. 2005. The hepatopulmonary syndrome: NO way out? Eur Respir J, 25:212.
40. Nakos G, Evrenoglou D, Vassilakis N, et al. 1993. Haemodynamics and gas exchange in liver cirrhosis: the effect of orally administered almitrine bimesylate. Respir Med, 87:93-8.
41. [NIH] National Institutes of Health. 2008. Pilot study of pentoxifylline for hepatopulmonary syndrome [online]: identifier: NCT00593658. Accessed on June 25, 2000. URL: http://clinicaltrials.gov/ct2/show/ NCT00593658?term=NCT00593658&rank=1.
42. Nunes H, Lebrec D, Mazmanian M, et al. 2001. Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats. Am J Respir Crit Care Med, 164:879-85.
43. Pizcueta P, Pique JM, Fernandez M, et al. 1992. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology, 103:1909-15.
44. Poterucha JJ, Krowka MJ, Dickson ER, et al. 1995. Failure of hepatopulmonary syndrome to resolve after liver transplantation and successful treatment with embolotherapy. Hepatology, 21:96-100.
45. Rabiller A, Nunes H, Lebrec D, et al. 2002. Prevention of gram-negative translocation reduces the severity of hepatopulmonary syndrome. Am J Respir Crit Care Med, 166:514-17.
46. Riegler JL, Lang KA, Johnson SP, et al. 1995. Transjugular intrahepatic portosystemic shunt improves oxygenation in hepatopulmonary syndrome. Gastroenterology, 109:978-83.
47. Robin ED, Horn B, Goris ML, et al. 1975. Detection, quantitation and pathophysiology of lung spiders. Trans Assoc Am Physicians, 88:202-16.
48. Robin ED, Laman D, Horn BR, et al. 1976. Platypnea related to orthodeoxia caused by true vascular lung shunts. N Engl J Med, 294:941-3.
49. Rodriguez-Roisin R, Roca J, Agusti AG, et al. 1987. Gas exchange and pulmonary vascular reactivity in patients with liver cirrhosis. Am Rev Respir Dis, 135:1085-92.
50. Rodriguez-Roisin R, Krowka MJ, Herve P, et al. 2004. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J, 24:861-80,
51. Rolla G, Brussino L, Colagrande P, et al. 1997. Exhaled nitric oxide and oxygenation abnormalities in hepatic cirrhosis. Hepatology, 26:842-7.
52. Rydell R, Hoffbauer FW. 1956. Multiple pulmonary arteriovenous fistulas in juvenile cirrhosis. Am J Med, 21:450-60.
53. Ryu JK, Oh JH. 2003. Hepatopulmonary syndrome: angiography and therapeutic embolization. Clin Imaging, 27:97-100.
54. Saad NEA, Lee DE, Waldman DL et al. 2007. Pulmonary arterial coil embolization for the management of persistent Type 1 hepatopulmonary syndrome after liver transplantation. J Vasc Interv Radiol, 18:1576-80.
55. Schenk P, Madl C, Rezaie-Majid S, et al. 2000. Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med, 133:701-6.
56. Schenk P, Fuhrmann V, Madl C, et al. 2002. Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. Gut, 51:853-9.
57. Schenk P, Schöniger-Hekele M, Fuhrmann V, et al. 2003. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology, 125:1042-52.
58. Scott VL, Dodson SF, Kang Y. 1999. The hepatopulmonary syndrome. Surg, Clin North Am, 79:23-41.
59. Selim KM, Akriviadis EA, Zuckerman E, et al. 1998. Transjugular intrahepatic portosystemic shunt: a successful treatment for hepatopulmonary syndrome. J Am Coll Gastroenterol, 93:455-8.
60. Seward JB, Hayes DL, Smith HC, et al. 1984. Platypnea-orthodeoxia: clinical profile, diagnostic work-up, management and report of 7 cases. Mayo Clin Proc, 59:221.
61. Shijo H, Sasaki H, Yuh K, et al. 1991. Effects of indomethacin on hepatogenic pulmonary angiodysplasia. Chest, 99:1027-9.
62. Shub C, Tajik AJ, Seward JB, et al. 1976. Detecting intrapulmonary right-to-left shunt with contrast echocardiography: observations in a patient with diffuse pulmonary arteriovenous fistulas. Mayo Clin Proc, 51:81-4.
63. Soderman C, Juhlin-Dannfelt A, Lagerstrand L, et al. 1994. Ventilation-perfusion relationships and central haemodynamics in patients with cirrhosis. Effects of a somatostatin analogue. J Hepatol, 21:52-7.
64. Stoller JK, Lange PA, Westveer MK, et al. 1995. Prevalence and reversibility of the hepatopulmonary syndrome after liver transplantation - The Cleveland Clinic Experience. West J Med, 163:133-8.
65. Swanson KL, Weiner RH, Krowka MJ. 2005. Natural history of hepatopulmonary syndrome: Impact of liver transplantation. Hepatology, 41:1122-29.
66. Thorens JB, Junod AF. 1992. Hypoxemia and liver cirrhosis: a new argument in favour of a diffusion-perfusion defect. Eur Respir J, 5:754-6.
67. Vedrinne JM, Duperret S, Bizollon T, et al. 1997. Comparison of transoesophageal and transthoracic contrast echocardiography for detection of an intrapulmonary shunt in liver disease. Chest, 111:1236-40.
68. Wang YW, Lin HC. 2005. Recent advances in hepatopulmonary syndrome. J Chin Med Assoc, 68:500-5.
69. White RE, Lynch-Nyhan A, Terry P, et al. 1988. Pulmonary arteriovenous malformations: techniques and long-term outcome of embolotherapy. Radiology, 169:663-9.
70. Williams A, Trewby P, Williams R, et al. 1979. Structural alterations to the pulmonary circulation in fulminant hepatic failure. Thorax, 34:447-53.
71. Wolfe JD, Tashkin DP, Holly FE, et al. Hypoxemia of cirrhosis: detection of abnormal small pulmonary vascular channels by a quantitative radionuclide method. Am J Med, 63:746-54.
72. Yamada R, Sato M, Kawabata M, et al. 1983. Segmental obstruction of the hepatic inferior vena cava treated with transluminal angioplasty. Radiology, 149:91-6.
73. Zamirian M, Aslani A, Shahrzad S. 2007. Left atrial volume: A novel predictor of hepatopulmonary syndrome. Am J Gastroenterol, 102:1392-6.
74. Zhang HY, Han DW, Wang XG, et al. 2005. Experimental study on the role of endotoxin in the development of hepatopulmonary syndrome. World J Gastroenterol, 11:567-72.
75. Zhang J, Ling Y, Tang L, et al. 2007. Pentoxifylline attenuation of experimental hepatopulmonary syndrome. J Appl Physiol, 102:949-55.